Fuxiang Zhou. "Disitamab vedotin combined with fruquintinib in patients with HER2-expressing or HER2 mutation/amplified metastatic colorectal cancer refractory to at least two standard regimens: A prospective, exploratory, single-arm study.." Journal of Clinical Oncology, 2025. doi:10.1200/jco.2025.43.16_suppl.e15562